Neoadjuvant endocrine therapy for breast cancer: An overview;Hormonothérapie néoadjuvante dans le cancer du sein: Revue de la littérature

Bulletin du Cancer

Volumn 91, Issue 1, 2004, Pages 55-62

  Domont, Julien ^a   Namer, Moise ^b   Khayat, David ^c   Spano, Jean Philippe ^c  

^a INSTITUT CURIE   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Aromatase inhibitors; Breast cancer; Endocrine therapy; Neoadjuvant; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; DOCETAXEL; EPIRUBICIN; EXEMESTANE; LETROZOLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; HORMONAL THERAPY; HORMONE SENSITIVITY; HUMAN; METASTASIS; PREOPERATIVE PERIOD; REVIEW;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NEOADJUVANT THERAPY; NITRILES; TAMOXIFEN; TRIAZOLES;

EID: 1242270530     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Hill C, Doyon F. Fréquence des cancers en France. Bull Cancer 2003 ; 90 : 207-13.
2. National Institute of Health (NIH) Consensus Development. Adjuvant therapy for breast cancer. Bethesda, 1-3 November 2000. J Natl Cancer Inst 2001 ; 93 : 979-89.
3. EBCTG. Tamoxifen for early breast cancer : an overview of the randomised trials. Lancet 1998 ; 351 : 1451-67.
4. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T. Anastrazole alone or in combination with tamoxifen versus tamoxifene alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : results of the ATAC (arimidex tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 2003 ; 98 : 1779-81.
5. Gazet JC, Coombes RC, Fort HT, et al. Assessement of the effect of pretreatment with neoadjuvant therapy on primary breast cancer. Br J Cancer 1996 ; 73 : 758-62.
6. Fisher B, Bryant J, Mamounas E, Wolmark N. Effect of pteopetative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998 : 16 ; 2672-85.
7. Gaskell DJ, Hawkins RA, Sangster K, Chetty U, Forrest APM. Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet 1989 ; 250 : 1044-6.
8. Robertson JFR, Ellis IO, Elston CW, Blamey RW. Mastectomy or tamoxifen as initial theapy fot operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 1992 ; 28A : 908-10.
9. Muss H. Breast cancer in older women. Semin Oncol 1996 ; 23 : 82-8.
10. Eierman W, Paepke J, Appfelstaedt J, et al. Preoperative treatment of menopausal breast cancer patients with letrozole; a randomised double-blind multicenter study. Ann Oncol 2001 ; 12 : 1527-32.
11. Ellis MJ, Coop A, Singh B. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2 positive, oestrogen receptor-positive primary breast cancer: evidence from a phase III randomised trial. J Clin Oncol 2001 ; 19 : 3808-16.
12. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetuxel. J Clin Oncol 2002 ; 20 : 1456-66.
13. Jacquillat C, Baillet F, Weil M. Results of a conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation of 98 patients with locally advanced breast cancer (IIIA-IIIB). Cancer 1988 ; 61 : 1977-82.
14. Fisher B, Mamounas EP. Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 1995 ; 13 : 537-40.
15. Bonnadonna G, Valagussa P, Brambilla C, Ferrari L. Preoperative chemotherapy in operable breast cancer. Lancet 1993 ; 341 : 1485.
16. Goldie JH, Coldman AJ, et al. A mathematic model for relating the drug sensitivity of tumor to their spontaneous mutation rate. Cancer Treat Rep 1979 ; 63 : 1723-33.
17. Skipper HE, Schabel FM, et al. Quantitative and cytokinetic studies in experimental tumot models. In : Holland JF, Frei E, eds. Cancer medicine. Philadelphia: Lean, Febiger 1973 : 629-650.
18. Fischer B, Gunduz N, Coyle J, et al. Presence of a growth stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989 ; 49 : 1996-2001.
19. Fischer B, Saffer E, Rudock C, et al. Effect of local or systemic treatment priot to primary tumor on the production and tesponse to a serum growth stimulating factor in mice. Cancer Res 1989 ; 49 : 2002-4.
20. De Friend DJ, Howell A, Nicholson RI, et al. Investigation of a ICI 182780 in women with primary breast cancer. Cancer Res 1994 ; 15 : 408-14.
21. Robertson JFR, Dixon M, Bundred N, et al. A randomised study comparing the anti-tumor effects of single-dose of faslodex with TAM in postmenopausal women with primary breast cancer prior to surgery. Breast Cancer Res Treat 1999 ; 57 : 31.
22. Boeddinghaus IM, Dowsett M, Smith IE, et al. Neoadjuvant arimidex or tamoxifen, alone or combined for breast cancer: PgR-related reductions in proliferation Marker Ki67. ProASCO 2000 [abst. 306].
23. De Jong PC, van de Ven J, Nortier JW, et al. Inhibition of intratumoral aromatase activity and oestradiol by exemestane in postmenopausal breast cancer patients: results of a double blind randomised study. ProASCO 2001 ; 20, 33a [abst. 130].
24. Geisler J, Detre S, Bernstsen H, et al. Influence of neoadjuvant anastrozole on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001 ; 7 : 1230-6.
25. Hortobaggy GN, Singletarty SE, McNeese MD. Treatment of Locally advanced and inflammatory breast cancer. In : Harris JR, Lippman ME, Morrow M, eds. Breast diseases. Philadelphia : Lippincott-Raven, 1996.
26. Scholl SM, Pierga JY, Asselain B, et al. Breast tumours response to primary chemotherapy predicts local and distant as well as survey. Eur J Cancer 1995 ; 31A : 1969-75.
27. Pierga JY, Mouret E, Diéras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000 ; 83 : 1480-7.
28. Abraham DC, Jones RC, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by IRM. Cancer 1996 ; 78 ; 91-100.
29. Gilles R, Guinebretierre JM, et al. Locally advanced breast cancer: contrast enhanced subtraction MR imaging of response to pteoperative chemotherapy. Radiology 1994 ; 191 : 633-8.
30. Wasser K, Sinn HP, Fink C, Klein SK, Junkermann H, Ludermann HP, et al. Accuracy of tumor size measurement in breast cancer using MRI is histological regression induced by neoadjuvant chemotherapy. Eur Radiol 2003 ; 13 : 1213-23.
31. Balu Maestro C, Brunetton JN, et al. Doppler couleur en pathologie mammaire. J Radiol 1991 ; 72 : 579-83.
32. Dehdashti F, Flanagan FL, Mortimer JE, et al. Positron emission tomographic assessment of metabolic flare to predict response of metastatic breast cancer to antioestrogen therapy. Eur J Nucl Med 1999 ; 26 : 51-6.
33. Inoue T, Kim EE, Wallace S, et al. Positron emission tomography using [18] fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer. Cancer Biother Radiopharm 1996 ; 11 : 235-45.
34. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicine-based neoadjuvant chemotherapy. J Clin Oncol 1999 ; 17 : 460-9.
35. Chevallier B, Mosseri V, Dauce JP, Bastit P, Julien JP, Asselain B. A prognostic score in histological node negative breast cancer. Br J Cancer 1990 ; 61 : 436-40.
36. Wilsher PC, Robertson JF, Chan SY, et al. Locally advanced breast cancer: early results of a randomised trial of multimodal thetapy versus initial hormone therapy. Eur J Cancer 1997 ; 33 : 45-9.
37. Tan SM, Cheung KL, Willsher PC, et al. Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy. Eur J Cancer 2001 ; 37 : 2331-8.
38. Mauriac L, Debled M, Durand M, Floquet A, Boulanger V, Dagada C, et al. Neoadjuvant tamoxifen for hormone-sensitive non metastatic breast carcinomas in early postmenopausal women. Ann Oncol 2002 ; 13 : 293-8.
39. Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozLe on tumor volume in postmenopausal women with breast cancer: a randomised, double-blind, single-center study. Clin Cancer Res 2000 ; 6 : 2229-35.
40. Milla-Santos A, Milla I, Rallo L, et al. Anastrozole as neoadjuvant therapy for hormone-dependent locally advanced breast cancer in posmenopausal patients. ProASCO 2002 [abst. 156].
41. Sanchez R, Duarte C, Perry F, et al. Open study evaluation of neoadjuvant hormonal therapy in permenopausal patients with advanced breast cancer. ProASCO 2002 [abst. 2034].
42. Dixon JM, Love CDB, Bellamy COC et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001 ; 66 : 191-9.
43. Dixon JM, Anderson T, et al. Phase 2 study of neoadjuvant exemestane in locally breast cancer. ProASCO 2001 ; 20, 40b [abst. 1908].
44. Wolf C, Hackl W, Kuemper S, et al. Preoperative chemoendocrine treatment for patients with primary breast cancer: a phase I study. ProASCO 2001 [abst. 1819].
45. Lichtenegger W, Hackl W, Huettner C, et al. Exemestane combined with weekly docetaxel as preoperative treatment for breast cancer. ProASCO 2001 [abst. 1832].
46. Wolf C, Kumper S, Krainck U, et al. Exemestane with/without fractionated epirubicin as preoperative treatment for patients with primary breast cancer: an exploratory phase II study of the GENARI study group. ProASCO 2002 [abst. 1989].
47. Herschman HR, et al. Prostaglandin synthase 2. Biochim Biophys Acta 1996 ; 1299 : 125-40.
48. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000 ; 60 ; 1306-11.
49. Simpson ER, Davis SR, et al. Aromatase and the regulation of oestrogen biosynthesis: some new perspectives. Endocrinology 2001 ; 142 ; 4589-94.
50. Pesenti E, Masferrer JL, Di salle E, et al. Effect of exemestane and celecoxib alone or in combination on DMBA-induced mammary carcinoma in rats. Breast Cancer Res Treat 2001 ; 69, 288 [abst. 445].
51. NSABP : the effect on primary tumor response of adding sequential taxotere to adriamycine and cyclophosphamide: preliminary results from NSABP protocol B-27. Breast Cancer Res Treat 2001 ; 69 : 210.